25B-NB

25B-NB
Clinical data
Other names	N-Benzyl-4-bromo-2,5-dimethoxyphenethylamine; N-Benzyl-2C-B; NB-2C-B
Drug class	Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen
Identifiers
	IUPAC name N-benzyl-2-(4-bromo-2,5-dimethoxyphenyl)ethanamine;
CAS Number	155639-26-2;
PubChem CID	10360487;
ChemSpider	8535936;
UNII	2D6Q55542W;
ChEMBL	ChEMBL292692;
CompTox Dashboard (EPA)	DTXSID701337023 ;
Chemical and physical data
Formula	C17H20BrNO2
Molar mass	350.256 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC(=C(C=C1CCNCC2=CC=CC=C2)OC)Br;
	InChI InChI=1S/C17H20BrNO2/c1-20-16-11-15(18)17(21-2)10-14(16)8-9-19-12-13-6-4-3-5-7-13/h3-7,10-11,19H,8-9,12H2,1-2H3; Key:XXLRSXIQVKHKPM-UHFFFAOYSA-N;

25B-NB, also known as N-benzyl-4-bromo-2,5-dimethoxyphenethylamine (N-benzyl-2C-B or NB-2C-B), is a recreational designer drug from the 25-NB subgroup of the substituted phenethylamine family, with psychedelic effects. It has a binding affinity (K_i) of 16 nM at the serotonin receptor 5-HT_2A and 90 nM at 5-HT_2C and reportedly has a potency in between that of 2C-B and 25B-NBOMe (NBOMe-2C-B). 25B-NB was first synthesized and described by Richard Glennon and colleagues in 1994. It was the first drug of the 25-NB family to be developed. Subsequently, modification of 25B-NB led to the development of the more well-known 25-NB family drugs such as 25I-NBOMe.